Bivalirudin used as alternative anticoagulant in carotid artery stenting: A single center observational study

Journal of Interventional Cardiology

Volumn 25, Issue 2, 2012, Pages 197-202

  Geisbüsch, Philipp ^a,b   Katzen, Barry T ^a   Peña, Constantino ^a   Benenati, James F ^a   Uthoff, Heiko ^a  

^a BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CAROTID ARTERY STENTING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DRUG SAFETY; FALSE ANEURYSM; FEMALE; HEART INFARCTION; HUMAN; INFECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STROKE;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBINS; CAROTID STENOSIS; FEMALE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; TICLOPIDINE;

EID: 84859711346     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00684.x     Document Type: Article

References (25)

1. Hirsh J, Raschke R,. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
2. Greinacher A, Warkentin TE,. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 2006; 118: 165-176.
3. White CM,. Thrombin-directed inhibitors: Pharmacology and clinical use. Am Heart J 2005; 149: S54-60.
4. Lee CJ, Ansell JE,. Direct thrombin inhibitors. Br J Clin Pharmacol 2011 Jan 17. doi:.
5. Kumar D, Dangas G, Mehran R, et al,. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators). Am J Cardiol 2010; 106: 941-945.
6. Skrupky LP, Smith JR, Deal EN, et al,. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy 2010; 30: 1229-1238.
7. Reed MD, Bell D,. Clinical pharmacology of bivalirudin. Pharmacotherapy 2002; 22: 105S-111S.
8. Shammas NW,. Bivalirudin: Pharmacology and clinical applications. Cardiovasc Drug Rev 2005; 23: 345-360.
9. Allie DE, Lirtzman MD, Wyatt CH, et al,. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: A safe and feasible alternative for renal and iliac interventions. J Invasive Cardiol 2003; 15: 334-342.
10. Kastrati A, Neumann FJ, Mehilli J, et al,. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696.
11. Katzen BT, Ardid MI, MacLean AA, et al,. Bivalirudin as an anticoagulation agent: Safety and efficacy in peripheral interventions. J Vasc Interv Radiol 2005; 16: 1183-1187;quiz 1187.
12. Stamler S, Katzen BT, Tsoukas AI, et al,. Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair. J Vasc Interv Radiol 2009; 20: 17-21.
13. Stone GW, White HD, Ohman EM, et al,. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907-919.
14. Ndrepepa G, Schulz S, Keta D, et al,. Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality. Am J Cardiol 2010; 105: 163-167.
15. Bonati LH, Dobson J, Algra A, et al,. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: A preplanned meta-analysis of individual patient data. Lancet 2010; 376: 1062-1073.
16. Rao AK, Pratt C, Berke A, et al,. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
17. Brott TG, Hobson RW, 2nd, Howard G, et al,. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11-23.
18. Blackshear JL, Cutlip DE, Roubin GS, et al,. Myocardial infarction after carotid stenting and endarterectomy: Results from the carotid revascularization endarterectomy versus stenting trial. Circulation 2011; 123: 2571-2578.
19. Ederle J, Dobson J, Featherstone RL, et al,. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): An interim analysis of a randomised controlled trial. Lancet 2010; 375: 985-997.
20. Stabile E, Sorropago G, Tesorio T, et al,. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: Results from a prospective randomized study. J Vasc Surg 2010; 52: 1505-1510.
21. Schneider LM, Polena S, Roubin G, et al,. Carotid stenting and bivalirudin with and without vascular closure: 3-year analysis of procedural outcomes. Catheter Cardiovasc Interv 2010; 75: 420-426.
22. Bush RL, Lin PH, Mureebe L, et al,. Routine bivalirudin use in percutaneous carotid interventions. J Endovasc Ther 2005; 12: 521-522.
23. Lin PH, Bush RL, Peden EK, et al,. Carotid artery stenting with neuroprotection: Assessing the learning curve and treatment outcome. Am J Surg 2005; 190: 850-857.
24. Pinto DS, Stone GW, Shi C, et al,. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol 2008; 52: 1758-1768.
25. Cohen DJ, Lincoff AM, Lavelle TA, et al,. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial. J Am Coll Cardiol 2004; 44: 1792-1800.